News | May 31, 2023
Synexa Joins CEPI in advancing global epidemic preparedness and response
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Farxiga is expected to have such a strong influence on the market due to the impressive results
Cautions against fragmented & siloed efforts in addressing the challenges faced by the world and underlined the need for collaborative efforts to ensure global health security
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Subscribe To Our Newsletter & Stay Updated
